Literature DB >> 27053693

Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and D6PK.

Martin Koestenberger1, Christian Apitz2, Hashim Abdul-Khaliq3, Georg Hansmann4.   

Abstract

Transthoracic echocardiography (TTE) is a useful method for non-invasive screening of patients at risk of pulmonary hypertension (PH). Since TTE often serves as the initial study before invasive cardiac catheterisation, misinterpretation of TTE variables may lead to missed or delayed diagnosis with devastating consequences for the patients, or unnecessary invasive diagnostics that have inheriting risks. Due to the heterogeneous anatomy in congenital heart disease, particularly the assessment of myocardial function in children with PH is challenging. Here, we present recommendations on the use of TTE in the screening, diagnosis and follow-up of patients with PH, and discuss the limitations of this non-invasive imaging technique. This expert consensus statement focuses on key TTE variables used to determine the pressure in the pulmonary artery, myocardial contractility and systolic and diastolic function of the RV and LV. A particular focus is on the TTE assessment of RV function and geometry. According to the published data on the application of TTE in PH in childhood, we suggest a structured approach for non-invasive assessment of pulmonary artery pressure and myocardial function that may help to identify patients with early ventricular deterioration and their response to advanced pharmacotherapy. In addition to clinical and biochemical markers, serial examination of patients with PH using a standardised TTE approach, determining conventional and several more novel echocardiographic variables may allow early diagnosis and treatment, better recognition of disease progression and guide tailored therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2016        PMID: 27053693     DOI: 10.1136/heartjnl-2014-307200

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  14 in total

1.  Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.

Authors:  Martin Koestenberger; Georg Hansmann
Journal:  Pediatr Cardiol       Date:  2017-08-07       Impact factor: 1.655

2.  Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations.

Authors:  Pedro Anuardo; Monica Verdier; Natali W S Gormezano; Gabriela R V Ferreira; Gabriela N Leal; Alessandro Lianza; Juliana C O A Ferreira; Rosa M R Pereira; Nadia E Aikawa; Maria Teresa Terreri; Claudia S Magalhães; Simone Appenzeller; Maria Carolina Dos Santos; Silvana B Sachetti; Claudio A Len; Gecilmara S Pilleggi; Simone Lotufo; Eloisa Bonfá; Clovis A Silva
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

3.  Artemisinin and Its Derivate Alleviate Pulmonary Hypertension and Vasoconstriction in Rodent Models.

Authors:  Changlei Bao; Qian He; Hui Wang; Yanan Sun; Yahang Xu; Yan Pan; Yadan Hu; Shichuang Zheng; Shuxin Liang; Ang Luo; Tanzilan Nahar; Jiwang Chen; Haiyang Tang; Ying Han
Journal:  Oxid Med Cell Longev       Date:  2022-06-17       Impact factor: 7.310

4.  Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: Results from the European Pediatric Pulmonary Vascular Disease Network.

Authors:  Martin Koestenberger; Alexander Avian; Andreas Gamillscheg; Hannes Sallmon; Gernot Grangl; Ante Burmas; Sabrina Schweintzger; Stefan Kurath-Koller; Gerhard Cvirn; Georg Hansmann
Journal:  Clin Cardiol       Date:  2018-08-18       Impact factor: 2.882

5.  Real-time 3D-echocardiography of the right ventricle-paediatric reference values for right ventricular volumes using knowledge-based reconstruction: a multicentre study.

Authors:  Ulrike Herberg; Florentina Smit; Christian Winkler; Robert Dalla-Pozza; Johannes Breuer; Kai Thorsten Laser
Journal:  Quant Imaging Med Surg       Date:  2021-07

6.  A novel echocardiographic approach indicates disease severity in pediatric pulmonary hypertension.

Authors:  Martin Koestenberger; Alexander Avian; Massimiliano Cantinotti; Katharina Meinel; Georg Hansmann
Journal:  Pediatr Int       Date:  2020-04-17       Impact factor: 1.524

7.  Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Authors:  Martin Koestenberger; Georg Hansmann
Journal:  Pulm Circ       Date:  2018 Jul-Sep       Impact factor: 3.017

8.  Left Ventricular Dysfunction and Plasmatic NT-proBNP Are Associated with Adverse Evolution in Respiratory Syncytial Virus Bronchiolitis.

Authors:  Moises Rodriguez-Gonzalez; Alvaro Antonio Perez-Reviriego; Ana Castellano-Martinez; Simon Lubian-Lopez; Isabel Benavente-Fernandez
Journal:  Diagnostics (Basel)       Date:  2019-07-27

9.  Subcostal Echocardiographic Imaging in Neonatal and Pediatric Intensive Care.

Authors:  Stefan Kurath-Koller; Martin Koestenberger; Georg Hansmann; Massimiliano Cantinotti; Cecille Tissot; Hannes Sallmon
Journal:  Front Pediatr       Date:  2021-06-24       Impact factor: 3.418

10.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.